---
title: "FDA Grants Fast Track Designation to MoonLake’s Sonelokimab for Palmoplantar Pustulosis"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/274516861.md"
datetime: "2026-02-02T13:00:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274516861.md)
  - [en](https://longbridge.com/en/news/274516861.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274516861.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/274516861.md) | [English](https://longbridge.com/en/news/274516861.md)


# FDA Grants Fast Track Designation to MoonLake’s Sonelokimab for Palmoplantar Pustulosis

MoonLake Immunotherapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to sonelokimab (SLK) for the treatment of moderate-to-severe palmoplantar pustulosis (PPP). The designation is supported by positive Phase 2 LEDA trial results and is expected to facilitate more frequent interactions with the FDA, earlier and more frequent written communication, and eligibility for Accelerated Approval, Priority Review, and Rolling Review, if applicable. The company plans to submit a Biologic License Application (BLA) for SLK in hidradenitis suppurativa (HS) in the second half of 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moonlake Immunotherapeutics published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001162492-en) on February 02, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### 相關股票

- [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-HK/quote/SBIO.US.md)
- [VG Health (VHT.US)](https://longbridge.com/zh-HK/quote/VHT.US.md)
- [iShares US Pharma (IHE.US)](https://longbridge.com/zh-HK/quote/IHE.US.md)
- [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-HK/quote/ARKG.US.md)
- [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-HK/quote/XBI.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-HK/quote/BBH.US.md)
- [MoonLake Immunotherapeutics (MLTX.US)](https://longbridge.com/zh-HK/quote/MLTX.US.md)
- [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/zh-HK/quote/IBBQ.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-HK/quote/PBE.US.md)
- [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-HK/quote/BIB.US.md)
- [Health Care Select Sector SPDR (XLV.US)](https://longbridge.com/zh-HK/quote/XLV.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-HK/quote/IBB.US.md)
- [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-HK/quote/FBT.US.md)

## 相關資訊與研究

- [Novartis Announces FDA Approval for Cosentyx for Pediatric Patients with Moderate to Severe Hidradenitis Suppurativa](https://longbridge.com/zh-HK/news/279080266.md)
- [NRx Pharma Says FDA Identifies No Bioequivalence Issues In Preservative-free Ketamine Application](https://longbridge.com/zh-HK/news/279426124.md)
- [Novartis Gains FDA Approval For Cosentyx In Pediatric Hidradenitis Suppurativa](https://longbridge.com/zh-HK/news/279221547.md)
- [Pfizer announces positive topline phase 2 results for next-generation CDK4 inhibitor, atirmociclib, in second-line metastatic breast cancer](https://longbridge.com/zh-HK/news/279429425.md)
- [Mirum Pharmaceuticals Executives Sell Shares](https://longbridge.com/zh-HK/news/279503772.md)